News

Argenx makes its New York debut

Monday 22 May 2017
Country
Belgium

Belgium-based Argenx NV has made its debut on the Nasdaq over-the-counter market in the US, capping what has been nearly a decade of successful antibody discovery and development. On 17 May, it announced the pricing of an initial public offering (IPO) of its shares that was set to yield $100 million.

Vertex gets regulatory nod

Thursday 18 May 2017
Country
United States

Vertex Pharmaceuticals Inc has received a new approval from the US Food and Drug Administration for its cystic fibrosis treatment Kalydeco (ivacaftor) that triples the number of rare gene mutations that the drug can treat to 33 from 10.

Money for Italian biotech

Thursday 18 May 2017
Country
Italy

A group of biotech entrepreneurs, led by a former executive at Novartis, has announced plans to raise €50 million for a fund that will invest in Italian life science. The fund is being managed by AurorA-TT, a technology transfer company set up in Milan earlier this year.

Celyad licenses technology to Novartis

Sunday 14 May 2017
Country
Belgium

Belgium-based Celyad SA, which used to go by the name of Cardio3 BioSciences SA, has secured a non-exclusive licensing agreement with Novartis giving the Swiss company rights to US patents for the production of allogeneic CAR T cells.

Adaptimmune funded through to late 2019

Sunday 14 May 2017
Country
United Kingdom

Following share offerings in March and April that raised a net $103.2 million, Adaptimmune Therapeutics Plc has sufficient liquidity to fund operations through to late 2019, according to the company’s first-quarter results.

Immunocore identifies new lead compound

Sunday 14 May 2017
Country
United Kingdom

The Oxford, UK oncology company Immunocore Ltd has identified a lead compound in its second discovery collaboration with GlaxoSmithKline Plc which is expected to have potential for treating triple negative breast cancers, oesophageal, gastric and ovarian cancers.

Takeda takes option on GammaDelta

Saturday 13 May 2017
Country
United Kingdom

Less than a year after its founding, GammaDelta Therapeutics Ltd has received an investment from Takeda Pharmaceutical Company Ltd, which sees promise in the UK company’s T cell platform as a source for new immunotherapies.

Pfizer in gene therapy deal

Saturday 13 May 2017
Country
United States

Pfizer Inc has expanded its portfolio of gene therapy assets following a licensing deal with Sangamo Therapeutics Inc giving it exclusive rights to a preclinical product for haemophilia A, a bleeding disorder caused by the lack of clotting factor VIII.

Ablynx awaits regulatory decision

Thursday 11 May 2017
Country
Belgium

Ablynx NV experienced a net cash outflow of €26.2 million in the first quarter as it maintained a high level of research and development spending to support its portfolio of therapeutic proteins to treat inflammatory, oncology and respiratory diseases.

Genmab books higher royalties

Thursday 11 May 2017
Country
Denmark

Royalties from the CD38-targeted antibody therapeutic Darzalex (daratumumab) were the main source of revenue for Genmab A/S in the 2017 first quarter. Developed by Genmab and licensed to Janssen Biotech Inc, the product is approved for the treatment of multiple myeloma.